Back to Journals » Journal of Experimental Pharmacology » Volume 10

Propranolol for the treatment of vascular sarcomas

Authors Wagner MJ, Cranmer LD, Loggers ET, Pollack SM

Received 5 April 2018

Accepted for publication 31 May 2018

Published 6 September 2018 Volume 2018:10 Pages 51—58

DOI https://doi.org/10.2147/JEP.S146211

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Andrew Yee

Peer reviewer comments 3

Editor who approved publication: Professor Bal Lokeshwar


Michael J Wagner,1,2 Lee D Cranmer,1,2 Elizabeth T Loggers,1,2 Seth M Pollack1,2

1Division of Medical Oncology, 2Clinical Research Division University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Abstract: Vascular sarcomas are abnormal proliferations of endothelial cells. They range from benign hemangioma to aggressive angiosarcoma, and are characterized by dysregulated angiogenic signaling. Propranolol is a β-adrenergic receptor inhibitor that has demonstrated clinical efficacy in benign infantile hemangioma, and is now being used experimentally for more aggressive vascular sarcomas and other cancers. In this review, we discuss the use of propranolol in targeting these receptors in vascular tumors and other cancers.

Keywords: propranolol, vascular sarcoma, angiosarcoma, β-blocker, cancer

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]